These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
259 related items for PubMed ID: 14730342
21. The use of lipid formulations of amphotericin B for systemic fungal infections. Leenders AC, de Marie S. Leukemia; 1996 Oct; 10(10):1570-5. PubMed ID: 8847891 [Abstract] [Full Text] [Related]
22. Liposomal and lipid-based formulations of amphotericin B. de Marie S. Leukemia; 1996 Jun; 10 Suppl 2():s93-6. PubMed ID: 8649062 [Abstract] [Full Text] [Related]
24. Should we continue using amphotericin B deoxycholate for the treatment of fungal infections? Adverse events and clinical outcomes. Garbino J, Markham L, Matulionyte R, Rives V, Lew D. Scand J Infect Dis; 2006 Jun; 38(2):110-3. PubMed ID: 16449001 [Abstract] [Full Text] [Related]
27. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Wingard JR, Kubilis P, Lee L, Yee G, White M, Walshe L, Bowden R, Anaissie E, Hiemenz J, Lister J. Clin Infect Dis; 1999 Dec; 29(6):1402-7. PubMed ID: 10585786 [Abstract] [Full Text] [Related]
30. Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporin. Ringdén O, Andström E, Remberger M, Svahn BM, Tollemar J. Bone Marrow Transplant; 1994 Dec; 14 Suppl 5():S10-4. PubMed ID: 7703925 [Abstract] [Full Text] [Related]
32. [Safety of long-term administration of conventional amphotericin B in oncology patients]. Doubek M, Mayer J, Horký D. Cas Lek Cesk; 2002 Mar; 141(5):156-9. PubMed ID: 11998223 [Abstract] [Full Text] [Related]